近日，普瑞巴林胶囊成功获得新加坡卫生科学局（HSA）颁发的药品注册证书，标志着该药物正式进入新加坡市场。普瑞巴林是一种广泛用于治疗神经性疼痛、癫痫部分性发作以及广泛性焦虑障碍的处方药，其作用机制是通过调节中枢神经系统中的钙通道，减少异常神经信号的传递，从而缓解疼痛和焦虑症状。此次获批不仅体现了该药品在质量、安全性和有效性方面符合国际高标准，也为中国制药企业拓展东南亚市场提供了重要契机。随着新加坡作为区域医疗与药品监管枢纽的地位日益提升，该注册证书的取得将有助于加快普瑞巴林在其他东盟国家的注册进程，进一步推动国产优质药品走向国际市场。同时，这也反映了中国医药产业在国际化战略中不断取得实质性进展，为全球患者提供更多可负担、高质量的治疗选择。
Recently, Pregabalin Capsules have successfully obtained a Product Registration Certificate from Singapore’s Health Sciences Authority (HSA), officially granting market access in Singapore. Pregabalin is a widely prescribed medication used to treat neuropathic pain, partial-onset seizures in epilepsy, and generalized anxiety disorder. It works by modulating calcium channels in the central nervous system, thereby reducing abnormal nerve signaling and alleviating pain and anxiety symptoms. This regulatory approval underscores the drug’s compliance with international standards for quality, safety, and efficacy. It also represents a significant opportunity for Chinese pharmaceutical companies to expand into Southeast Asian markets. Given Singapore’s growing role as a regional hub for healthcare and pharmaceutical regulation, this certification is expected to accelerate the registration process of Pregabalin in other ASEAN countries, further facilitating the global outreach of high-quality, domestically produced medicines. Moreover, this milestone reflects the tangible progress China’s pharmaceutical industry is making in its internationalization strategy, offering more affordable and effective treatment options to patients worldwide.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/20178.html